The Institute for Clinical and Economic Review (ICER) announced its intention to evaluate the comparative clinical effectiveness and value of multiple myeloma treatments idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp). A BLA submission for ciltacabtagene autoleucel is expected by end of 2020 and an FDA decision on idecabtagene vicleucel is due in early 2021.
Furthermore, a review of ICER’s Evidence Report on multiple myeloma will occur during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in April 2021. Key posting dates and public comment periods for this assessment will be available on ICER’s website. Comments from all interested stakeholders are welcome until September 17, 2020 at 5 PM ET. For more information about the review and Open Input period, visit ICER’s website.
